43 results about "Murine tumor" patented technology

The invention discloses a nano system for tumor radioimmunotherapy and a preparation method and application thereof, and belongs to the technical field of biological medicines.The system modifies bacteria outer membrane vesicles (OMVs) through engineering to enable the bacteria outer membrane vesicles to carry magnetite nanoparticles (Fe3O4NPs) and an ATR inhibitor VE822, the Fenton reaction activity of the Fe3O4NPs and the synergistic effect of the ATR inhibitor for inhibiting DNA damage repair are utilized, and the tumor radioimmunotherapy effect is improved. DNA damage is amplified, DNA damage reaction (DDR) is inhibited, generation of hydroxyl radicals (. OH) under radiation is enhanced, radiation resistance of tumor cells is reduced, immune reaction is reactivated, infiltration of effector T cells to tumors is improved, growth of mice tumors is remarkably inhibited, and an effective strategy is provided for tumor radioimmunotherapy.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of medicines for preventing and treating hysteromyoma. The traditional Chinese medicine composition comprises spina gleditsiae, polygonum cuspidatum, dandelion, sargentgloryvine stem, codonopsis pilosula, chinaroot greenbrier, radix paeoniae rubra, salvia miltiorrhiza, lindera aggregata and corydalis tuber. The traditional Chinese medicine composition can obviously inhibit the tumor size of a rat with hysteromyoma, reduce the uterine coefficient, reduce the number and size of myoma and improve the pathological state of the uterus; moreover, the content of E2, P and ER in serum can be reduced, and the traditional Chinese medicine composition has a good effect of treating hysteromyoma.

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

The invention relates to the technical field of biological medicines, in particular to a biphenyl aromatic amide compound and application thereof in preparation of a medicine for treating leukemia. The biphenyl aryl amide compound has the activity of efficiently inhibiting leukemia cell proliferation, and provides a safe and efficient candidate drug molecule for treating leukemia; the preparation process of the biphenyl aromatic amide compound is simple and easy to implement, and the reaction conditions are mild; the biphenyl aryl amide compound has excellent performance of inhibiting mouse tumor growth, can be used for anti-leukemia drugs, and has a good development prospect.

The invention provides an aptamer conjugate targeting triple negative breast cancer as well as a preparation method and application of the aptamer conjugate. A non-natural nucleic acid aptamer capable of entering triple negative breast cancer cells in a targeted internalization manner is identified by using a cell internalization screening technology, and the aptamer is further coupled with a cytotoxic agent through a pH-responsive degradable linker CL2A to construct an aptamer conjugate based on non-natural nucleic acid. The aptamer conjugate can specifically target and internalize to enter triple negative breast cancer cells, and accurately release cytotoxic agents. The aptamer conjugate disclosed by the invention can better target a tumor lesion in a triple-negative breast cancer tumor-bearing mouse, efficiently inhibits the growth of the tumor of the triple-negative breast cancer tumor-bearing mouse, has no obvious biological toxicity, and provides a new means for targeted therapy of triple-negative breast cancer.

The invention belongs to the technical field of biological medicines, and relates to an A.muciniphila bacterium and an application of an outer membrane vesicle of the A.muciniphila bacterium in relieving chronic stress-mediated colorectal cancer progress. The product provided by the invention can effectively improve the influence of chronic stress on the tumor growth of colorectal cancer mice, and specifically comprises the following steps: inhibiting and / or relieving weight loss, relieving intestinal function damage, relieving tumor load increase, reducing tumor cell proliferation activity, and relieving or inhibiting the growth, invasion and metastasis of tumors. The invention provides a new treatment strategy for colorectal cancer patients accompanied by chronic stress.

The invention belongs to the technical field of medicines, and generally relates to application of N-acetyl-L-tyrosine and an N-acetyltransferase strain for expressing tyrosine in preparation of tumor treatment drugs or anti-tumor immune activation drugs for elderly individuals. Researches find that N-acetyl-L-tyrosine and a tyrosine-expressing N-acetyltransferase strain can significantly inhibit mouse tumors, which shows that the mouse tumors grow slowly or the number of the mouse tumors is reduced. The N-acetyl-L-tyrosine can also regulate anti-tumor immunity, and is expressed as promoting TCF1 expression and increasing the proportion of depleted precursor T cells. In the elderly, the curative effect is particularly prominent. The results show that N-acetyl-L-tyrosine and related strains thereof can be used for tumor treatment and anti-tumor immune aging regulation.

The present invention provides novel human fms-related tyrosine kinase 3 (FLT3) antigen-binding proteins, such as antibodies, with improved FLT3 binding affinity and / or anti-tumor activity. The FLT3 antibodies of the present invention are generated by mutation of parental FLT3 antibodies and are tested in vitro in binding assays and in vivo in murine tumor models and human patient tumor samples. The antibodies of the present invention are provided in monospecific constructs or bispecific FLT3xCD3 antibody forms and exhibit excellent target affinity and / or tumor cell killing. The present invention also relates to methods for generating the antigen-binding proteins of the present invention, as well as nucleic acids encoding them, vectors expressing them, and host cells. The present invention further relates to methods of using the FLT3 antigen-binding proteins (ABPs) of the present invention for treating or diagnosing diseases such as leukemia.

To provide methods for assessing immune response in murine models.SOLUTION: The present invention provides a method comprising: obtaining a sample from a murine model; detecting the expression level of a panel of genes in the sample, wherein the panel comprises at least 50 genes; comparing the expression level of the panel to a reference expression level; and assessing the immune response in the murine model.SELECTED DRAWING: None

The application discloses a kind of mouse tumor cell culture devices, including device ontology, multiple placing racks are installed in device ontology, multiple placing racks top are all set with placing groove, the inside of multiple placing racks is all provided with access mechanism, access mechanism includes multiple placing plate, the inside of multiple placing plate is all separated into multiple placing chamber by multiple partition, the inside of multiple placing chamber is provided with correction mechanism, and drive mechanism is provided in device ontology.In the application, when multiple culture dishes need to be placed in the device ontology for cultivation, the access mechanism provided in the device ontology can be used to place the multiple culture dishes one by one, without manually placing and adjusting the spacing of the multiple culture dishes repeatedly, improving the efficiency of placing the multiple culture dishes in the device ontology, reducing the time of the culture dishes in the external environment, and improving the survival rate of mouse tumor cell cultivation.

This invention discloses 1-(1H-imidazol-2-yl)-β-carbamoline-3-formyl-Arg-Gly-Asp-Val, its preparation method, its activity in inhibiting tumor cell invasion and migration, and its activity in inhibiting tumor metastasis to the lungs in Lewis mice. Therefore, this invention discloses its application in the preparation of drugs for treating cancer metastasis.

The application discloses application of a separating enzyme inhibitor in preparation of an antitumor drug, and the separating enzyme inhibitor is toxoflavin and a derivative thereof. The compound can inhibit, at a molecular level, cleavage activity of an important proteinase, namely separating enzyme, on one subunit Scc1 of a mucin; at a cellular level, the toxoflavin derivative Walrycin B can inhibit proliferation of cancer cells such as human cervical cancer (HeLa), liver cancer (HepG2), breast cancer (MCF-7) and prostate cancer (PC3), and can arrest the cell cycle of the cancer cells at a G2 / M phase; and at an allogeneic transplantation tumor animal model, the Walrycin B can significantly inhibit growth of a mouse tumor.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

The invention belongs to the field of biological medicines, and relates to application of an intestinal flora metabolite citraconic acid in prevention and treatment of colorectal cancer. The citraconic acid can significantly inhibit the proliferation of colorectal cancer cells, shows concentration dependence and time dependence, reduces the proportion of EdU positive red stained cells, inhibits the migration distance of the colorectal cancer cells and the number of migrated cells, inhibits the volume and weight of mouse tumors, and reduces tumor tissue necrosis and the number of pathological nuclear division cells. The expression of Ki67 in tumor tissues of mice is reduced.

The invention discloses application of lactobacillus mucosa or equol in preparation of a sensitizing colorectal cancer immunotherapy drug. Lactobacillus mucosa LMSJ001 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.29885. The lactobacillus mucosa LMSJ001 is preserved in the China General Microbiological Culture Collection Center (CGMCC). According to the application disclosed by the invention, the curative effect of the PD-1 antibody on microsatellite stable (immunotherapy insensitive) colorectal cancer mice is enhanced through the lactobacillus mucosa LMSJ001, and the tumor growth of the colorectal cancer mice can be remarkably inhibited through prophylactic or therapeutic gavage. The lactobacillus mucosa LMSJ001 can generate a metabolite equol, the equol can sensitize the curative effect of a PD-1 antibody on microsatellite stable (immunotherapy insensitive) colorectal cancer mice, the colorectal cancer is remarkably inhibited in vivo and in vitro, and ferroptosis of colorectal cancer cells is promoted. Based on the unique functions, the lactobacillus mucosa LMSJ001 or a metabolite equol of the lactobacillus mucosa LMSJ001 can be cooperated or complemented with other means, can be used for preparing a pharmaceutical composition, and has a very wide application prospect.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The present invention discloses a nanosystem for tumor radioimmunotherapy, its preparation method and application, belonging to the technical field of biomedicine. This system is engineered to modify bacterial outer membrane vesicles (OMVs) to carry magnetite nanoparticles (Fe3O4NPs) and the ATR inhibitor VE822. By using the synergistic effect of the Fenton reaction activity of Fe3O4NPs and the inhibition of DNA damage repair by the ATR inhibitor, DNA damage is amplified and the DNA damage response (DDR) is inhibited, the generation of hydroxyl radicals (·OH) under radiation is enhanced, the radiation resistance of tumor cells is reduced, the immune response is reactivated, the infiltration of effector T cells into tumors is improved, and the growth of tumors in mice is significantly inhibited, providing an effective strategy for tumor radioimmunotherapy.

The invention discloses a PD-1 / PD-L1 immunotherapy acquired drug-resistant mouse subcutaneous tumor model construction method based on in-vivo multi-dimensional immune landscape evolution, and relates to the field of animal model construction. Comprising the following steps: preparing tumor cells: resuscitating and amplifying an MC38 colonic adenocarcinoma cell strain, and preparing a single-cell suspension; establishing a basic model: inoculating the MC38 single-cell suspension under the skin of a homologous C57BL / 6 mouse, and establishing a tumor-bearing mouse model; drug resistance induction and screening: after the tumor grows to a predetermined volume, applying continuous treatment pressure of an anti-PD-1 or anti-PD-L1 antibody to the tumor-bearing mouse. Firstly, the tumor volume of mice in a treatment group is compared with the average volume of a control group at the same time point, response mice with the tumor volume obviously smaller than that of the control group are screened out, and primary drug-resistant individuals are excluded. Performing dynamic immune monitoring sampling; and processing and analyzing the sample. The preclinical model has the characteristics of repeatability and dynamic monitoring, and overcomes the defects of the existing preclinical model.

The invention belongs to the field of medicines, and discloses an antibody conjugate, the antibody conjugate is obtained by coupling a connecting structure, bortezomib and an antibody, the antibody conjugate has extremely strong drug sensitivity, and when the antibody conjugate is singly used or combined with cis-platinum, the antibody conjugate shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.

The invention relates to the technical field of biology, and discloses an identification kit and an identification method for mouse tumor-associated macrophage subsets. The identification kit comprises a packaging box as well as a PBS (phosphate buffer solution) reagent bottle, a cell digestive juice reagent bottle, a red blood cell lysis buffer reagent bottle, an antigen confining liquid reagent bottle, a phycoerythrin (PE) labeled F4 / 80 antibody reagent bottle, a docoxanthin-chlorophyll-protein complex (PerCP) labeled CD68 antibody reagent bottle and fluorescein isothiocyanate (FITC) which are arranged in the packaging box and a labeled C1Q antibody reagent bottle. The identification kit can be used for identifying whether C1Q positive tumor-related macrophages appear in colorectal cancer tumor tissues or not; identifying whether the C1Q positive tumor-related macrophages are differentiated from bone marrow-derived macrophages or not; and identifying whether the C1Q positive tumor-associated macrophages are differentiated from tissue resident macrophages or not. According to the invention, the understanding of the innate immune cell subpopulation in the colorectal tumor immune microenvironment can be improved, and a new target spot is provided for diagnosis and treatment of colorectal cancer.

The invention discloses an application of miR408 in preparation of a medicine for treating tumors. The invention finds that the ginseng miR408 transferred into the body of a mouse through the exosome can still maintain better integrity and stability; through overexpression of ginseng miR408 in breast cancer MCF-7 and MDA-MB-231 cells, it is found that after overexpression of ginseng miR408, proliferation, migration and invasion of tumor cells can be significantly inhibited, cell apoptosis can be promoted, and CCND1 mRNA and protein expression levels can be reduced; a mouse gavage experiment also shows that the ginseng miR408 can significantly inhibit the growth of breast cancer mouse tumors. The application shows that the ginseng miR408 can enter the body to treat the breast cancer in an exosome manner, a new way is provided for treating the breast cancer, the problems of untoward effects and the like existing in existing medicine treatment are solved, and a new action mechanism and a new research direction are provided for ginseng in the aspect of breast cancer treatment.

The invention discloses a mouse tumor cell culture device which comprises a device body, a plurality of placing frames are installed in the device body, placing grooves are formed in the tops of the placing frames, storing and taking mechanisms are arranged in the placing frames, and each storing and taking mechanism comprises a plurality of placing plates. The interiors of the multiple containing plates are divided into multiple containing cavities through multiple partition plates, correction mechanisms are arranged in the multiple containing cavities, and a driving mechanism is arranged in the device body. According to the device, when multiple culture dishes need to be placed in the device body for culture, the multiple culture dishes can be sequentially placed through the access mechanism arranged in the device body, the multiple culture dishes do not need to be manually and repeatedly placed and the distance between the multiple culture dishes does not need to be adjusted, and the efficiency of placing the multiple culture dishes in the device body is improved; the time of the culture dish in the external environment is shortened, so that the survival rate of mouse tumor cell culture is improved.

The invention provides a cytokine mRNA (messenger Ribonucleic Acid) combination medicine and application thereof. The combined medicine comprises mRNA (messenger ribonucleic acid) for coding 4-1BBL protein, mRNA for coding CD40L protein and mRNA for coding IL-36 gamma protein. After the combined medicine is given to a tumor model mouse, the tumor volume of the mouse can be remarkably reduced. Compared with drugs of other protein types, the cytokine mRNA combined drug has the advantages of short production cycle, good safety, quick effect and low price.

This invention belongs to the field of medicinal chemistry, specifically relating to ionizable phospholipids for nucleic acid delivery and their applications. The technical problem this invention aims to solve is the limited variety of ionizable phospholipids currently available for preparing LNPs for mRNA delivery. The technical solution of this invention is to provide a novel ionizable phospholipid molecule that can be used to prepare nucleic acid delivery carriers and LNP formulations prepared based on it. LNP formulations prepared using the ionizable phospholipids of this invention as raw materials exhibit good stability. Experiments show that the LNPs of this invention can efficiently deliver therapeutic RNA to various human and murine tumor cells and achieve high levels of protein expression, demonstrating unique advantages and promising application prospects in this field.

The present invention relates to the field of biomedicine, and more particularly to biphenyl arylamide compounds and their use in the preparation of leukemia treatment drugs. The biphenyl arylamide compounds have the activity of effectively inhibiting the proliferation of leukemia cells, providing safe and effective candidate drug molecules for the treatment of leukemia. The preparation process of the biphenyl arylamide compounds is simple and easy, and the reaction conditions are mild. The biphenyl arylamide compounds have excellent performance in inhibiting tumor growth in mice, and can be used as anti-leukemia drugs, showing good development prospects.

The invention relates to application of galectin-1 (Gal-1) as an immune checkpoint in preparation of a tumor immunotherapy drug and the drug, and provides a new strategy for tumor immunotherapy targeting the new immune checkpoint. The lactose and the derivative thereof can inhibit the immune checkpoint by competing Gal-1 on the surfaces of cancer cells and immune cells, and have no obvious toxic or side effect; by knocking out B4GATL1 to reduce protein galactosylation, the Gal-1 level of tumor metastasis to T cells can be remarkably reduced, so that the activation and function of the T cells are enhanced; besides, the lactose synthetase component LALBA is overexpressed in the mouse tumor, so that de novo synthesis of lactose in the tumor microenvironment can be realized, and further the CD8 + T cell mediated immune response is enhanced. In combination with the anti-tumor effect and economic cost of lactose, a wide and feasible thought is provided for cancer treatment.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating uterine fibroids. The traditional Chinese medicine composition comprises Gleditsia sinensis L. thorns, giant knotweed, dandelion, Sargentgloryvine stem, radix codonopsis, smilax, red peony root, salvia miltiorrhiza, lindera and corydalis. The traditional Chinese medicine composition can obviously inhibit tumor size of uterine fibroid rats, reduce uterine coefficient, reduce the number and size of myoma, and improve the pathological state of the uterus; and can reduce the content of E2, P and ER in serum, and has a good effect on treating uterine fibroids.

The utility model relates to the technical field of mouse tumor measurement, and provides a background plate for in-vitro mouse tumor measurement photographing, which comprises a base plate, a first mark, a second mark and at least one third mark are arranged on the base plate, the first mark extends along a first direction, the second mark extends along a second direction, and the third mark extends along a third direction. The second identifier extends in the second direction, the first direction is perpendicular to the second direction, the first identifier and the second identifier intersect at the original point, and the third identifier and the first identifier are arranged in parallel at an interval and intersect with the second identifier. According to the background plate for measuring and photographing the tumor of the in-vitro mouse, the first identifier, the second identifier and the third identifier are arranged on the base plate, so that after the tumor of the in-vitro mouse is measured and photographed, the size information of the tumor of the in-vitro mouse can be directly read out, the step of synthesizing a coordinate system through a computer is omitted, and the working efficiency is improved. The operation time of in-vitro mouse tumor photographing measurement can be shortened, and manpower and material resources are saved.

The present invention discloses a circular RNA circTFDP2 and its siRNA application in the diagnosis and treatment of prostate cancer. The fluorescence quantitative PCR method finds that the expression of circTFDP2 in prostate cancer tissue is significantly increased, and the expression level is positively correlated with the Gleason score. The expression level of circTFDP2 detected in the urine of prostate cancer patients after prostate massage is positively correlated with the expression level of prostate cancer tissue. The expression level of circTFDP2 in prostate cancer cells is significantly higher than that in normal prostate epithelial cells. After overexpression, circTFDP2 can significantly promote the proliferation, migration and invasion of prostate cancer, as well as the tumor growth and distant metastasis of xenograft mouse tumor models in vivo. Targeted knockdown of circTFDP2 using siRNA can significantly inhibit the proliferation, migration, invasion and in vivo tumor growth and distant metastasis of prostate cancer cells. circTFDP2 plays an important role in the diagnosis and / or prognosis evaluation and treatment of prostate cancer, and can be used as a diagnostic biomarker and therapeutic target for prostate cancer.

The disclosure provides methods and compositions, e.g., kits and microarray, for assessing the immune response in a murine tumor model based on the expression of a gene panel that characterizes tumor immune interactions.